Drug Trial Radar · NCT03816176
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Aug 22, 2019
Primary completion
Dec 14, 2022
Study completion Dec 14, 2022
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
Conditions
- Invasive Mucormycosis
- Invasive Aspergillosis
Interventions
Isavuconazonium sulfateDrug
Intravenous (IV) infusion
Isavuconazonium sulfateDrug
Oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose to 30 days after the last dose (maximum 210 Days)
- Percentage of Participants With All - Cause Mortality Through Day 42Time frame: Baseline up to 42 days
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital, Los Angeles
Los Angeles, California
University of California - Los Angeles
Los Angeles, California
Children's Hospital of Orange County
Orange, California
Children's National Medical Center
Washington D.C., District of Columbia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Site BE32001
Ghent, Belgium
Site BE32002
Leuven, Belgium
Site ES34002
Barcelona, Spain
Site ES34003
Madrid, Spain
Site ES34001
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.